Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives

• المؤلفون الرئيسيون: Yuan Fang (مؤلف), Guochao Liao (مؤلف), Bin Yu (مؤلف)
• التنسيق: كتاب
• منشور في: Elsevier, 2020-07-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Blocking the MDM2/X-P53 protein-protein interaction has been widely recognized as an attractive therapeutic strategy for the treatment of cancers. Numerous small-molecule MDM2 inhibitors have been reported since the release of the structure of the MDM2-P53 interaction in 1996, SAR405838, NVP-CGM097,...